- Home
- RPAY vs CELC Comparison
RPAY vs CELC Comparison
Compare RPAY & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPAY
- CELC
- Stock Information
- Founded
- RPAY 2006
- CELC 2011
- Country
- RPAY United States
- CELC United States
- Employees
- RPAY N/A
- CELC N/A
- Industry
- RPAY Business Services
- CELC Medical Specialities
- Sector
- RPAY Consumer Discretionary
- CELC Health Care
- Exchange
- RPAY Nasdaq
- CELC Nasdaq
- Market Cap
- RPAY 387.2M
- CELC 440.0M
- IPO Year
- RPAY N/A
- CELC 2017
- Fundamental
- Price
- RPAY $4.63
- CELC $11.60
- Analyst Decision
- RPAY Buy
- CELC Strong Buy
- Analyst Count
- RPAY 9
- CELC 5
- Target Price
- RPAY $8.06
- CELC $30.80
- AVG Volume (30 Days)
- RPAY 1.7M
- CELC 140.7K
- Earning Date
- RPAY 08-07-2025
- CELC 08-13-2025
- Dividend Yield
- RPAY N/A
- CELC N/A
- EPS Growth
- RPAY N/A
- CELC N/A
- EPS
- RPAY N/A
- CELC N/A
- Revenue
- RPAY $309,647,000.00
- CELC N/A
- Revenue This Year
- RPAY N/A
- CELC N/A
- Revenue Next Year
- RPAY $8.28
- CELC N/A
- P/E Ratio
- RPAY N/A
- CELC N/A
- Revenue Growth
- RPAY 2.26
- CELC N/A
- 52 Week Low
- RPAY $3.59
- CELC $7.58
- 52 Week High
- RPAY $10.86
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- RPAY 46.86
- CELC 49.88
- Support Level
- RPAY $4.54
- CELC $11.85
- Resistance Level
- RPAY $4.74
- CELC $13.40
- Average True Range (ATR)
- RPAY 0.20
- CELC 0.70
- MACD
- RPAY -0.06
- CELC -0.09
- Stochastic Oscillator
- RPAY 10.98
- CELC 35.83
About RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.